(NASDAQ: IBRX) Immunitybio's forecast annual revenue growth rate of 127% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.96%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.07%.
Immunitybio's revenue in 2026 is $82,555,000.On average, 7 Wall Street analysts forecast IBRX's revenue for 2026 to be $215,067,146,835, with the lowest IBRX revenue forecast at $150,384,483,530, and the highest IBRX revenue forecast at $257,213,806,844. On average, 6 Wall Street analysts forecast IBRX's revenue for 2027 to be $524,385,611,648, with the lowest IBRX revenue forecast at $267,093,007,589, and the highest IBRX revenue forecast at $808,331,373,450.
In 2028, IBRX is forecast to generate $980,089,601,364 in revenue, with the lowest revenue forecast at $639,971,275,403 and the highest revenue forecast at $1,400,620,484,538.